# A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07749586/  
OnCo record `nct07749586` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Arvinas Inc., now recruiting.

## Summary

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07749586 by Arvinas Inc., with 499 participants planned, started 2026-07-29 and due to reach its primary completion in 2031-03-31. Interventions recorded: ARV-6723, Pembrolizumab and SOC.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07749586
- Phase: 1/2
- Setting: A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- Sponsor: Arvinas Inc.
- Enrolled: 499

## Sources

- ClinicalTrials.gov NCT07749586: https://clinicaltrials.gov/study/NCT07749586

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Arvinas](https://onco.cc/companies/arvinas/)

---
JSON: https://onco.cc/api/v1/entities/nct07749586.json